Category: Patent Profiles

    By Donald Zuhn — Isis Pharmaceuticals, Inc. announced today that the U.S. Patent and Trademark Office has issued notices of allowance for U.S. Application Nos. 10/281,312 and 10/281,297.  According to the company’s press release, the two allowances "significantly expand" the scope of Isis’ Crooke patent estate — a family of patents based on…

    By Donald Zuhn — Helix BioMedix, Inc. announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,407,940, which is directed to hexapeptides that exhibit antimicrobial activity against infections caused by a variety of pathogens.  According to Helix Biomedix’s statement, the ‘940 patent covers a family of hexapeptide antimicrobial agents,…

    By Jason Derry — Tobira Therapeutics Inc. has announced that the U.S. Patent and Trademark Office has issued Patent No. 7,371,772.  According to Tobira, the ‘772 patent, which is assigned on its face to Takeda Pharmaceutical Co. Ltd., covers a compound that Tobira currently has in Phase I development for the treatment of…

    By Donald Zuhn — Ulysses Pharmaceuticals announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,410,974, which is directed to a class of compounds that exhibit antibiotic activity against a wide spectrum of microorganisms, including organisms that are resistant to multiple antibiotic families (the so-called "superbugs").  According to…

    By Kwame Mensah — Last month, Chemokine Therapeutics Corp. announced that it has been granted U.S. Patent Nos. 7,354,899, entitled "Methods of treating Autoimmune Diseases Comprising Administering CXCR4 Antagonists" and 7,368,425, entitled "Cyclic Peptides for Modulating Growth of Neo-Vessels and Their Use in Therapeutic Angiogenesis."  With the issuance of the ‘899 and ‘425…

    By Donald Zuhn — Yesterday, StemCells, Inc. announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,361,505, which is directed to multipotent neural stem cell compositions.  While the ‘505 patent is assigned to Neurospheres Holdings Ltd., StemCells notes that it has exclusively licensed the patent.  As we reported earlier…

    By Donald Zuhn — Redpoint Bio Corp. announced earlier this month that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,341,842, which is directed to methods of methods for identifying modulators of the TRP8-mediated taste response.  Such modulators can be used as flavor enhancers in foods, beverages, or pharmaceuticals to…

    By Donald Zuhn — OPKO Health, Inc. announced yesterday that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,345,027, which is directed to methods of inhibiting the expression of human vascular endothelial growth factor (VEGF), degrading VEGF mRNA, inhibiting angiogenesis, or treating an angiogenic disease using a specific short interfering…

    By Donald Zuhn — Commonwealth Biotechnologies, Inc. announced today that it has been granted U.S. Patent No. 7,338,761.  According to Commonwealth’s press release, while the ‘761 patent is assigned to Vigen Laboratories, the patent is exclusively licensed to CBI Services, a Commonwealth business unit, which developed the claimed invention under contract to Vigen…

    By Baltazar Gomez — Last Thursday, OREXIGEN Therapeutics, Inc. announced that the U.S. Patent and Trademark Office mailed a Notice of Allowance for a patent application directed to the treatment of obesity using zonisamide, either alone or in combination with other drugs.  According to OREXIGEN, the allowed application will complement U.S. Patent No.…